# US 12,060,380 B2 · Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,060,380 B2
- Document ID: US12060380B2
- Status: Granted
- Kind: B2
- Application number: 17/257,917
- Filed: 2019-07-05
- Published: 2021-09-23
- Granted: 2024-08-13
- Earliest claimed: 2018-07-06
- Assignees: Kancera AB
- Applicants: Kancera AB
- Inventors: Jan Vågberg; Styrbjörn Byström; Elisabeth Olsson; Mattias Jönsson
- Web page: https://patentgrep.com/patent/US12060380B2

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

## Claims

### Claim 1

A compound of formula I,
wherein
R1 represents aryl or pyridyl, both of which are optionally substituted by one or more groups selected from halo, —CN, —C(O)NR3R4, —S(O)2R5, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, wherein
the latter three groups are optionally substituted by one or more F;
R2 represents H or C1-6 alkyl optionally substituted by one or more F;
R3 and R4 each independently represent H or C1-6 alkyl optionally substituted by one of more F;
R5 represents C1-6 alkyl optionally substituted by one or more F;
represents
wherein “” indicates a point of attachment to the rest of the molecule;
Q1 and Q2 each independently represent H or —PO(OR6)(OR7);
Q3 represents H or —CH2OPO(OR6)(OR7); and
Q4 represents—CH2OPO(OR6)(OR7);
wherein R6 and R7 each independently represent H, C1-4 alkyl or C2-4 alkenyl;
wherein at least one of Q1, and Q2, Q3 or Q4 represents—PO(OR6)(OR7) or —CH2OPO(OR6)(OR7);
or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, wherein R1 represents phenyl or pyridyl, both of which are optionally substituted by one or more fluoro, chloro, bromo, —CN, —C(O)NR3R4 or —S(O)2Me group.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein R1 represents phenyl or 5-chloropyridin-2-yl.

### Claim 4 (depends on 1)

A compound as claimed in claim 1, wherein R2 represents methyl.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein one of Q1 and Q2, Q3 or Q4 represents—PO(OR6)(OR7) or —CH2OPO(OR6)(OR7), and the remainder of Q1, and (if present) Q2 or Q3 represent H.

### Claim 6 (depends on 1)

A compound as claimed in claim 1, wherein
represents

### Claim 7 (depends on 6)

A compound as claimed in claim 6, wherein
represents

### Claim 8 (depends on 6)

A compound as claimed in claim 6, wherein
represents

### Claim 9 (depends on 5)

A compound as claimed in claim 5, wherein Q1 represents—PO(OR6)(OR7).

### Claim 10 (depends on 7)

A compound a claimed in claim 7, wherein Q2 represents—PO(OR6)(OR7).

### Claim 11 (depends on 8)

A compound as claimed in claim 8, wherein Q3 represents—CH2OPO(OR6)(OR7).

### Claim 12 (depends on 5)

A compound as claimed in claim 5, wherein
represents

### Claim 13 (depends on 1)

A compound as claimed in claim 1, wherein the compound is a compound of formula IA,
wherein R1, R2, Q1, and
are as defined in any one of the preceding claims, or a pharmaceutically-acceptable salt thereof.

### Claim 14 (depends on 1)

A compound as claimed in claim 1, wherein R6 and R7 each represent H.

### Claim 15 (depends on 1)

A compound as claimed in claim 1, wherein R6 and R7 each represent methyl or each represent ethyl, or wherein R6 represents iso-propyl and R7 represents H.

### Claim 16 (depends on 1)

A compound as claimed in claim 1, wherein the pharmaceutically-acceptable salt is an ammonium salt or an alkali metal salt.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1, including pharmaceutically-acceptable salts thereof, in admixture with one or more pharmaceutically-acceptable excipient.

### Claim 18 (depends on 17)

A pharmaceutical composition as claimed in claim 17, wherein the pharmaceutical composition further comprises water and less than 20% (w/w) of solubilising excipients.

### Claim 19 (depends on 18)

A pharmaceutical composition as claimed in claim 18, wherein the pharmaceutical composition is in the form of an aqueous solution.

### Claim 20 (depends on 3)

A pharmaceutical composition as claimed in claim 3, wherein the composition is in the form of a powder.

### Claim 21 (depends on 1)

A method of treating and/or preventing a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 comprising administering to a patient in need thereof, a therapeutically effective amount of a compound as defined in claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

### Claim 23 (depends on 21)

The method of claim 21, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from macular degeneration, pulmonary arterial hypertension, asthma, pulmonary fibrosis, atopic dermatitis, pruritus, osteoarthritis, osteoporosis, aplastic anaemia, ankylosing spondylitis, multiple sclerosis, systemic sclerosis, rheumatoid arthritis, atherosclerosis, unstable angina, myocardial infarction, carotid artery diseases, chronic heart failure, inflammatory cardiomyopathy, peripheral artery disease, diabetes, Alzheimer's disease, traumatic brain injury, chronic pain, fibromyalgia, neuropathic pain, chemotherapy-induced pain, intervertebral disc herniation, cancer, liver cirrhosis, IgA nephropathy, renal inflammation, lupus, ischemia reperfusion injury, ischemic acute renal failure, contrast-induced kidney injury, colitis, Crohn's disease, inflammatory bowel disease, pancreatitis, human immunodeficiency virus-1, human immunodeficiency virus-associated dementia, stroke, Parkinson's disease, depression, anxiety, schizophrenia and autism spectrum disorders.

### Claim 24 (depends on 21)

The method of claim 21, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from myocardial infarction, arteriosclerosis, multiple sclerosis, rheumatoid arthritis, Crohn's disease, pancreatitis, neuropathic pain, chemotherapy-induced pain and cancer.

### Claim 25 (depends on 21)

The method of claim 21, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from atopic dermatitis, multiple sclerosis, rheumatoid arthritis, atherosclerosis, myocardial infarction, chronic heart failure, inflammatory cardiomyopathy, fibromyalgia, neuropathic pain, chemotherapy-induced pain, B-cell lymphomas, breast cancer, IgA nephropathy, lupus, ischemic acute renal failure and pancreatitis.

### Claim 26 (depends on 1)

A combination product comprising:
(I) a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof; and
(II) one or more other therapeutic agent that is useful in the treatment or prevention of a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1,
wherein each of components (I) and (II) is formulated in admixture, optionally with a pharmaceutically-acceptable excipient, such as a pharmaceutically-acceptable adjuvant diluent or carrier.

### Claim 27 (depends on 17)

A kit-of-parts comprising:
(a) a pharmaceutical composition as defined in claim 17; and
(b) a pharmaceutical composition comprising one or more other therapeutic agent that is useful in the treatment or prevention of a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1, formulated in admixture with a pharmaceutically-acceptable excipient,
which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

### Claim 28 (depends on 1)

A process for the preparation of a compound as defined in claim 1, which process comprises:
(a) for compounds wherein Q1represents—PO(OR6)(OR7), wherein R6 and R7 are as defined above,
(i) reacting a compound of formula II
wherein R1 and R2 are as defined above; and
represents
with phosphorus oxychloride in the presence of a suitable solvent and a suitable base; then
(ii) adding water or R6OH/R7OH to the reaction mixture;
(b) for compounds wherein Q2 represents—PO(OR6)(OR7),
reacting a compound of formula III
wherein:
R1 and R2 are as defined above; and
PG1 represents a suitable oxygen protecting group;
in the presence of phosphorus pentachloride, a suitable solvent and, optionally, a suitable base;
(c) for compounds wherein Q3 or Q4 represents—CH2OPO(OR6)(OR7) and at least one of R6 and R7 represents C1-4 alkyl or C2-4 alkenyl,
reacting a compound of formula II
wherein R1 and R2 are as defined above; and
represents
with a compound of formula IV
wherein R6 and R7 are as defined above with the proviso that at least one of R6 and R7 represents C1-4 alkyl or C2-4 alkenyl and LG1 represents a suitable leaving group;
in the presence of a suitable base and a suitable solvent;
(d) for compounds wherein Q3 or Q4 represents—CH2OPO(OH)2,
(i) reacting a compound of formula II
wherein R1 and R2 are as defined above; and
represents
with a compound of formula V
wherein R8 and R9 represent C1-6 alkyl and LG2 represents a suitable leaving group;
in the presence of a suitable base and a suitable solvent; and
(ii) reacting the product formed in the presence of a suitable acid and a suitable solvent.

### Claim 29 (depends on 1)

A compound as claimed in claim 1, wherein the compound is selected from the group consisting of:
(2R)-2-[(2-Amino-5-{[1-(2-fluorophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(2-chlorophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(5-chloropyridin-2-yl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(3-fluoropyridin-2-yl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(3-cyanophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(3-carbamoylphenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-{[2-Amino-5-({1-[4-(methylsulfonyl)phenyl]ethyl}sulfanyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino}-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[4-(methylsulfonyl)benzyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-({2-Amino-5-[(1-pyridin-2-ylethyl)sulfanyl][1,3]thiazolo[4,5-d]pyrimidin-7-yl}amino)-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dimethyl phosphate;
(2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[11,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[11,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl bis(1-methylethyl) phosphate;
(2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[11,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl 1-methylethyl hydrogen phosphate;
(2R)-2-[(2-Amino-5-{[1-(2-fluorophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(2R)-2-[(2-Amino-5-{[1-(2-chlorophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(2R)-2-[(2-Amino-5-{[1-(5-chloropyridin-2-yl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(2R)-2-[(2-Amino-5-{[1-(3-fluoropyridin-2-yl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(2R)-2-[(2-Amino-5-{[1-(3-cyanophenyl)ethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
[7-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-imino-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[1-(2-Fluorophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-imino[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[1-(2-Chlorophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-imino[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[1-(5-Chloropyridin-2-yl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-imino[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[7-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-imino-5-[(1-pyridin-2-ylethyl)sulfanyl][1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[1-(3-Fluoropyridin-2-yl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-imino[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[1-(3-Cyanophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-imino[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
[5-{[(1S)-1-(5-Chloropyridin-2-yl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-2-oxo[1,3]thiazolo[4,5-d]pyrimidin-3(2H)-yl]methyl dihydrogen phosphate;
(2R)-2-[(5-{[(1S)-1-(5-chloropyridin-2-yl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-4-Methyl-2-({2-oxo-5-[(1-pyridin-2-ylethyl)sulfanyl]-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl}amino)pentyl dihydrogen phosphate;
(2R)-4-Methyl-2-{[5-({1-[4-(methylsulfonyl)phenyl]ethyl}sulfanyl)-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentyl dihydrogen phosphate;
(2R)-2-[(5-{[1-(3-Carbamoylphenyl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(5-{[1-(2-Chlorophenyl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(5-{[1-(3-Cyanophenyl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate;
(2R)-2-[(5-{[(1S)-1-(5-Chloropyridin-2-yl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dimethyl phosphate;
(2R)-2-[(5-{[(1S)-1-(5-Chloropyridin-2-yl)ethyl]sulfanyl}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl diethyl phosphate;
(7-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)phosphoramidic acid;
(5-{[1-(2-Chlorophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2-yl)phosphoramidic acid;
(7-{[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino}-5-[(1-pyridin-2-ylethyl)sulfanyl][1,3]thiazolo[4,5-d]pyrimidin-2-yl)phosphoramidic acid;
(5-{[1-(3-Cyanophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)phosphoramidic acid;
(5-{[1-(3-Fluoropyridin-2-yl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)phosphoramidic acid;
Diethyl (7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-5-1{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate;
Dimethyl (7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-5-1{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate;
Diethyl (5-{[1-(2-chlorophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate;
Diethyl (7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-5-[(1-pyridin-2-ylethyl)sulfanyl][1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate;
Diethyl (5-{[1-(3-cyanophenyl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate; and
Diethyl (5-{[1-(3-fluoropyridin-2-yl)ethyl]sulfanyl}-7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2-yl)amidophosphate, or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 13)

A compound as claimed in claim 13, wherein
R1 represents phenyl;
R2 represents methyl;
represents
Q1 represents—PO(OR6)(OR7);
Q2 represents H; and
R6 and R7 each independently represent H, C1-4 alkyl or C2-4 alkenyl, or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

A method of treating and/or preventing cancer, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound as defined in claim 30.

### Claim 32 (depends on 31)

A method as claimed in claim 31, wherein the compound is (2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)aminol-4-dihydrogen phosphate
or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

A method as claimed in claim 32, wherein the cancer is ovarian cancer.

### Claim 34 (depends on 32)

A method as claimed in claim 32, wherein the cancer is lung cancer.

### Claim 35 (depends on 32)

A method as claimed in claim 32, wherein the cancer is prostate cancer.

### Claim 36 (depends on 32)

A method as claimed in claim 32, wherein the cancer is liver cancer.

### Claim 37 (depends on 32)

A method as claimed in claim 32, wherein the cancer is pancreatic cancer.

### Claim 38 (depends on 32)

A method as claimed in claim 32, wherein the cancer is B-cell lymphomas.

### Claim 39 (depends on 32)

A method as claimed in claim 32, wherein the cancer is breast cancer.

### Claim 40 (depends on 30)

A method of treating and/or preventing a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1, selected from the group consisting of heart failure, ischemia refusion injury, atherosclerosis, stroke and ischemic acute renal failure, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound as defined in claim 30.

### Claim 41 (depends on 40)

The method as claimed in claim 40, wherein the compound is (2R)-2-[(2-Amino-5-{[(1S)-1-phenylethyl]sulfanyl}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentyl dihydrogen phosphate
H2N or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is heart failure.

### Claim 43 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL3 is chronic heart failure.

### Claim 44 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is ischemia reperfusion injury.

### Claim 45 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is atherosclerosis.

### Claim 46 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is stroke.

### Claim 47 (depends on 41)

A method as claimed in claim 41, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is ischemic renal failure.
